reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Sharad Kumar S.P
- Wim Lewi
- ING Helpdesk
Benelux Morning Notes
Aalberts: Preview - steady in difficult markets. ABN AMRO: 1Q24 overshadowed by weaker capital, even if a strong set. AEGON: 1Q24 Preview (trading update). Alfen: Preview - clarity on one-off Pacto costs crucial. B&S Group: Bolt-on acquisition in Personal Care. Belgian telcos: BIPT notes that fibre cooperation negotiations not ready by 15 May. EVS: 1Q24 preview. Euronext: Another record, with Beats by Boujnah. Montea: €12m acquisition in the Port of Ghent. Staffing: Dutch Perio...
PROX PROXIMUS SA DE DROIT PUBLIC
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
EVS EVS BROADCAST EQUIPMENT SA
RAND RANDSTAD NV
MONT MONTEA SCA
AALB AALBERTS N.V.
BRNL BRUNEL INTERNATIONAL N.V.
TWEKA TKH GROUP N.V. CERT
OBEL ORANGE BELGIUM SA
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
AGN AEGON N.V.
- Jacob Mekhael
- Lynn Hautekeete
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Secures 19m via global offering, extends runway to 1Q25
MaaT completed a global offering (reserved offering and primary bid offering) of approx. 2.3m new ordinary shares at a price of € 8 per share (discount of approx. 14% vs. last close) for gross proceeds of € 19.2m (net proceeds € 17.3m). The funds lift the financing overhang for MaaT and extend the company's runway to early 1Q25 (previously end 3Q24). This provides funding beyond the topline readout (ORR) from the phase 3 (ARES) trial of MaaT013 in aGvHD expected in mid 4Q24, which we view as the...
MaaT Pharma annonce le succès de son Offre Globale de 19,2 millions d’...
LYON, France--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE ET LES INFORMATIONS QU’IL CONTIENT SONT RESTREINTS ET NE SONT PAS DESTINES A LA DIFFUSION, A LA PUBLICATION OU A LA DISTRIBUTION, EN TOUT OU PARTIE, DIRECTEMENT OU INDIRECTEMENT, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD OU AUX ETATS-UNIS OU DANS TOUT AUTRE JURIDICTION DANS LAQUELLE UNE TELLE DIFFUSION, PUBLICATION OU DISTRIBUTION SERAIT ILLEGALE. CE COMMUNIQUE EST ETABLI A TITRE D’INFORMATION UNIQUEMENT ET NE CONSTITUE PAS, NI NE CONTIENT AUCUNE INVITATION, SOLLICITATION, RECOMMANDATION, OFFRE OU CONSEIL A QUICONQUE...
MaaT Pharma lance une augmentation de capital d’un montant approximati...
LYON, France--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE ET LES INFORMATIONS QU’IL CONTIENT SONT RESTREINTS ET NE SONT PAS DESTINES A LA DIFFUSION, A LA PUBLICATION OU A LA DISTRIBUTION, EN TOUT OU PARTIE, DIRECTEMENT OU INDIRECTEMENT, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD OU AUX ETATS-UNIS OU DANS TOUT AUTRE JURIDICTION DANS LAQUELLE UNE TELLE DIFFUSION, PUBLICATION OU DISTRIBUTION SERAIT ILLEGALE. CE COMMUNIQUE EST ETABLI A TITRE D’INFORMATION UNIQUEMENT ET NE CONSTITUE PAS, NI NE CONTIENT AUCUNE INVITATION, SOLLICITATION, RECOMMANDATION, OFFRE OU CONSEIL A QUICONQUE...
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
- Thomas Vranken
MaaT Pharma Business update and milestones ahead
MaaT Pharma provides a broad overview of its recent activities and expected milestones. We can expect a number of updates from MaaT's pipeline in the coming months, the most notable of which is the primary endpoint readout (28 day GI-ORR) from the Ph3 ARES trial of enema MaaT013 in aGvHD, which is expected mid 4Q24. We reiterate our € 15 TP and Buy rating.
MaaT Pharma fait le point sur ses activités et les principaux jalons a...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, fait le point sur ses activités et rappelle les principales étapes attendues pour l’année 2024. Hervé Affagard, directeur général et co-fondateur de MaaT Pharma, a déclaré : « nous avançons avec confiance vers les résultats de la Phase 3 pour MaaT013, tout en continuant à atteindre des jalons clés et à créer de la valeur...
MaaT Pharma Provides a Business Update and Highlights Key Milestones E...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024. Hervé Affagard, CEO and co-founder of MaaT Pharma said: “We're confidently advancing towards Phase 3 results for MaaT013, meeting milestones and delivering value for shareholders. Recent data at the EBMT annual congress underscores MaaT013's potential in aGvHD whe...
- ING Helpdesk
MaaT Pharma: Information mensuelle relative au nombre total de droits ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem Therapies™ (MET)1 visant à améliorer la survie des patients atteints de cancers, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 30 avril 2024. Place de cotation : Euronext Paris Code ISIN : FR0012634822 Site web : Date Nombre total d’actions composant le capital...
- Michiel Declercq
bpost 1Q24 Conference call feedback
1Q24 sales decreased 5.3% to € 993m, or 3.2% below CSS expectations driven by soft results in N-A. Although the 1Q24 adj. EBIT of € 62.1m came in below expectations (kbcse: € 71.6m, css: € 69.7m), we want to highlight that the adj. EBIT was impacted by € 7.7m in M&A costs related to the Staci acquisition. Excluding this effect, profitability was in line with expectations driven by solid cost savings in E-logistics. Additionally, bpost mentioned that it does not expect any restructuring costs in ...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- ING Helpdesk
Benelux Morning Notes
Aperam: In-line 1Q24 EBITDA, FCF marked by WC build, 2Q24 guidance below consensus. Ayvens: Taking the brakes off. BAM: Not the best start to the year. bpost: 1Q24 in line with consensus but beat vs INGF, no outlook yet. Brunel International: good set of 1Q24 results – 5% beat on EBIT, comforting trends. B&S Group: Preview - should be a non-event. DEME Group: Preview - should be a non-event. D'Ieteren: Febiac April registrations flat YoY, VW brands up 8.4%. GBL: NAV per share in ...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Sharad Kumar S.P
- Wim Hoste
- Wim Lewi
- Stefano Toffano
- Wim Gille
Bpost : Still in a challenging environment
>Top-line pressures and one-off costs - Bpost experienced pressure on both its Q1 24 revenues as well as its operating earnings. Group operating income (i.c. revenue) for the quarter came in at € 993m and adjusted EBIT at € 62m, respectively -3% and -11% vs. ccs, and -6% and -3% vs. our estimates. Bpost’s results continue to be driven by (a slowing) Belgium and E-Logistics Eurasia, while E-Logistics NA performed poorly once again due to challenging market conditions. ...
- Frank Claassen
bpost - Waiting for impact of press negotiations
• The Q1-24 REBIT was somewhat below expectations, mainly on higher corporate costs. No concrete FY24 guidance as not all negotiations on press distribution are finalized yet and impact is still unclear.• The planned acquisition of Staci can strategically be justified, but in our view it looks stretched financially, both on multiple paid and on resulting leverage. • Although multiples appear undemanding, we stick to Hold. There are still many uncertainties.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.